WegovyvsOzempic

The verdict

Wegovy scores 8.4/10 vs Ozempic at 8.3/10. Detailed breakdown below.

1. Top pick

   1

   

   #1· Editor's Choice

   Editor's ChoiceBest for CV Risk

   

   Wegovy

   FDA-approved semaglutide for chronic weight management

   • ✓Average 15% weight loss in clinical trials (STEP 1)
   • ✓FDA-approved with extensive safety record
   • ✓Weekly dosing

   ✓FDA-approved✓Brand-name✓Once-weekly injection✓GLP-1 receptor agonist✓Insurance eligible

   8.4/10

   Editorial score

   See offer →

   Read review+ Pin to compare
2. 2

   

   Runner-up

   Ozempic

   Semaglutide approved for type 2 diabetes

   • ✓Strong A1C reduction in T2D
   • ✓Often covered by insurance for diabetes indication

   ✓Off-label use✓Once-weekly injection✓GLP-1 receptor agonist✓Insurance eligible

   8.3/10

   Editorial score

   See offer →

   Read review+ Pin to compare

Side-by-side specs

Effectiveness: Wegovy vs Ozempic

Wegovy (Semaglutide) and Ozempic (Semaglutide) both belong to the GLP-1 receptor agonist class, but their molecular structure and dosing differ enough to produce different real-world outcomes. Head-to-head trial data is limited; most comparisons come from cross-trial analysis of pivotal studies (STEP-1, SURMOUNT-1, SELECT, SUSTAIN).

On weight loss, Wegovy typically shows stronger placebo-adjusted reductions at 68 weeks, with greater proportions of patients reaching ≥15% body-weight loss. For type 2 diabetes patients, A1C reduction tends to track with the drug's underlying glucose-handling mechanism — single-agonist semaglutide compounds (Wegovy, Ozempic, Rybelsus) yield ~1.5% A1C drop, while dual GIP/GLP-1 agonists (Mounjaro, Zepbound) frequently exceed 2.0%.

Side effects: what to expect

GI side effects dominate the first 8-12 weeks of GLP-1 therapy regardless of which drug you start on. Nausea (35-45%), diarrhea (15-25%), constipation (15-20%), vomiting (10-15%), and headache (10-15%) are the most reported. Wegovy and Ozempic share this profile; the difference is usually in titration aggressiveness and individual tolerance, not the drug itself.

More serious but rare adverse events — pancreatitis, gallbladder disease, kidney injury during dehydration, and the boxed warning for medullary thyroid cancer in rodent models — apply to the entire GLP-1 class. If you have a personal or family history of MTC or MEN2, neither Wegovy nor Ozempic is appropriate. Talk to your prescribing physician about your risk profile before starting either.

Cost & insurance

Without insurance coverage, both Wegovy and Ozempic run between $1,000 and $1,400 per month at list price. Coverage decisions hinge on whether your plan treats the drug as a weight-loss medication (often excluded from formulary) or a diabetes medication (typically covered). Medicare Part D specifically excludes weight-loss indications under current rules, so a Wegovy prescription is denied even though Ozempic (same molecule) is covered for T2D — a gap that drives many switching decisions.

Manufacturer savings cards can lower out-of-pocket cost to as little as $25-$650/month for commercially insured patients depending on plan tier. If you're uninsured or your plan rejects coverage, compounded semaglutide and tirzepatide from licensed 503A/503B pharmacies are typically 60-80% cheaper but carry quality-variability and supply-chain risks that brand drugs don't.

Who should choose Wegovy?

• You prioritize the strongest available weight-loss data and your insurance covers it, or you're willing to pay out of pocket via savings card.
• You have a cardiovascular risk profile that benefits from the trial evidence supporting this drug's class indication.
• Your prescriber is familiar with the titration schedule and your plan's prior authorization workflow.

Who should choose Ozempic?

• You prefer the alternative active ingredient based on tolerability, availability in your area, or insurance coverage.
• You had difficulty with prior Wegovy side effects and want to try a different molecule.
• Your prescribing clinic stocks it, has experience with its titration, or your pharmacy shows lower wait times.

Switching between them

Switching from Wegovy to Ozempic (or vice versa) is generally straightforward but requires a careful titration restart, not a direct dose swap. Your prescriber will typically pause for 1 week, then begin the new drug at its lowest dose regardless of where you were on the original. This minimizes GI side effects from a full-strength reintroduction. Expect 4-12 weeks before reaching the maintenance dose on the new medication.

Reasons people switch include: insurance formulary changes, shortage of the original drug, intolerable side effects, plateauing weight loss, or moving from a single-agonist to a dual-agonist compound. The choice should always go through your prescribing physician — do not self-switch using compounded products without medical supervision.

Bottom line

Wegovy is our editorial pick in this matchup with an overall score of 8.4/10, edging out Ozempic at 8.3/10. The score reflects a weighted average of clinical efficacy, safety profile, cost transparency, and access — not just trial outcomes. For most patients comparing these two, insurance coverage and pharmacy access will outweigh the scoring differential. Verify both with your prescriber and plan before committing.